The Phase 3 clinical trial (NCT03872401) investigating evolocumab (Repatha) for patients at high cardiovascular risk without prior myocardial infarction or stroke reached its primary completion date on 2025-07-25. This large study enrolled 12,301 participants to assess the effect of evolocumab on major cardiovascular events.
Background
Evolocumab is being studied for its potential to reduce major cardiovascular events in adults at high risk, specifically those without a history of myocardial infarction or stroke. The trial focuses on patients with Coronary Heart Disease (CHD).
Trial design
The study, identified as NCT03872401, is a Phase 3 clinical trial. It enrolled 12,301 participants to assess the effect of evolocumab on major cardiovascular events. The trial included adults at high cardiovascular risk without a prior myocardial infarction or stroke, focusing on those with Coronary Heart Disease (CHD). Participants were randomized to receive either evolocumab or placebo.
What this means
The primary completion of this Phase 3 trial marks a significant milestone in the evaluation of evolocumab for a specific high-risk cardiovascular population. While results are not yet available, the completion of data collection indicates that the study has gathered the necessary information to assess the drug's effect on major cardiovascular events in patients with Coronary Heart Disease (CHD) who have not previously experienced a myocardial infarction or stroke. Clinicians and researchers will await the full analysis and publication of these findings to understand the potential implications for patient care.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT03872401, titled "Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke," was posted on 2025-07-25 on clinicaltrials.gov.